[{"id":"6624a35f-cee8-4450-8d7f-b7b9c40ad3a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01647828","created_at":"2023-02-16T00:00:29.876Z","updated_at":"2024-07-02T16:35:55.487Z","phase":"Phase 1b/2","brief_title":"A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer","source_id_and_acronym":"NCT01647828","lead_sponsor":"OncoMed Pharmaceuticals, Inc.","biomarkers":" NOTCH3","pipe":" | ","alterations":" NOTCH3 expression • NOTCH3 overexpression","tags":["NOTCH3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NOTCH3 expression • NOTCH3 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • tarextumab (OMP-59R5)"],"overall_status":"Completed","enrollment":" Enrollment 217","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2023-02-15"}]